These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5727161)

  • 1. Parenteral manufacturing and legal regulations.
    Tamura LK
    Bull Parenter Drug Assoc; 1968; 22(6):261-6. PubMed ID: 5727161
    [No Abstract]   [Full Text] [Related]  

  • 2. I. Federal regulations concerning use of asbestos filters in manufacturing parenteral drugs.
    Casola AR
    Bull Parenter Drug Assoc; 1975; 29(5):216-8. PubMed ID: 1182330
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of the Food and Drug Administration's current good manufacturing practices regulations to pharmacy practice: a legal view.
    Fink JL
    Contemp Pharm Pract; 1979; 2(4):202-5. PubMed ID: 10244540
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of consultants in the parenteral industry.
    Agalloco JP
    J Parenter Sci Technol; 1986; 40(6):277-83. PubMed ID: 3819981
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA regulations and guidelines.
    Rothschild A
    J Parenter Sci Technol; 1990; 44(1):26-9. PubMed ID: 2313489
    [No Abstract]   [Full Text] [Related]  

  • 6. When does compounding become manufacturing?
    Gushee J
    J Am Vet Med Assoc; 1994 Jul; 205(2):235-6. PubMed ID: 7928585
    [No Abstract]   [Full Text] [Related]  

  • 7. The parenteral drug industry: recent findings.
    Fry EM
    J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464
    [No Abstract]   [Full Text] [Related]  

  • 8. II. Views of the pharmaceutical industry on the regulations.
    Newmark H
    Bull Parenter Drug Assoc; 1975; 29(5):218-21. PubMed ID: 1182331
    [No Abstract]   [Full Text] [Related]  

  • 9. Reaction of FDA to a fundamental change in the nature of regulations.
    Kennedy D
    J Parenter Drug Assoc; 1979; 33(1):17-20. PubMed ID: 253023
    [No Abstract]   [Full Text] [Related]  

  • 10. Separate manufacturing standards needed for veterinary drugs: AVMA.
    J Am Vet Med Assoc; 1996 Feb; 208(4):461. PubMed ID: 8603886
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug development history, "overview," and what are GCPs?
    Heilman RD
    Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 13. Lessons learned from good manufacturing practice noncompliance.
    Peskoe MP
    Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986
    [No Abstract]   [Full Text] [Related]  

  • 14. Manufacturing misdeeds cost Abbott record-breaking payment.
    Lewis C
    FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
    [No Abstract]   [Full Text] [Related]  

  • 15. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality control and good manufacturing practices: safety and efficacy of commercial herbals.
    Awang DV
    Food Drug Law J; 1997; 52(3):341-4. PubMed ID: 10343036
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products.
    Bull Parenter Drug Assoc; 1976; 30(6):265-79. PubMed ID: 1000103
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of good manufacturing practice regulations to investigational biologic products.
    Goebel PW
    J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865
    [No Abstract]   [Full Text] [Related]  

  • 20. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.